Consumer guide for cancer drugs may be an effective decision-making aide
the ONA take:
The American Society of Clinical Oncology task force of cancer physicians, patient advocates, and insurance and pharmaceutical company representatives has devised a “Value Framework” for available cancer drugs. The decision aide is intended to help physicians and patients weigh the pluses and minuses of treatment options for a wide range of cancers.
The Value Framework uses a rating system to assess a drug’s effectiveness in extending life for cancer patients and the number and severity of side effects. Although cost is not a direct factor in a drug’s net health benefit score, it is a significant factor in patient decisions on treatment and was crucial to the development of the decision aide.
Factors that make up a drug’s net health benefit index is how many more months of progression-free survival clinical trial participants had compared with those on standard treatments, number and severity of toxicities or unwanted side effects. The decision aide would also provide the treatment’s monthly cost.
One drawback of the Value Framework is that much of its initial information is based on established medical practices and research that predates current precision medicine practices. As the genetics of cancers advance, many drugs are found to offer benefit to a subset of patients, rather than to a wide group.
The task force is optimistic that the Value Framework will be able to keep up with the advances being made in precision medicine. They anticipate that the value of certain treatment regimens may be refined over time.
The American Society of Clinical Oncology task force has devised a “Value Framework” for available cancer drugs.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Breast Cancer Deaths Decrease Sharply Since 2000
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|